Susan Bobulsky serves as Chief Commercial Officer for Minimal Residual Disease (MRD) at Adaptive Biotechnologies Corp., where she leads the commercial strategy, sales, and marketing efforts for the company's groundbreaking clonoSEQ assay and related immune medicine platforms. With over 20 years of experience in biotechnology and diagnostics, Bobulsky has been instrumental in driving Adaptive's expansion in oncology, particularly in advancing MRD testing to improve patient outcomes in blood cancers like multiple myeloma and lymphoma. Her leadership has accelerated market adoption, forging key partnerships with leading cancer centers and pharmaceutical companies to integrate Adaptive's technologies into clinical practice. Prior to joining Adaptive in 2019, Bobulsky held senior commercial roles at Roche Diagnostics and Genentech, where she spearheaded the U.S. launch of innovative diagnostic and therapeutic portfolios, achieving over $500 million in annual revenue growth. At Roche, she built high-performing teams that expanded access to personalized medicine solutions, earning her the company's Global Sales Leadership Award. Her expertise in navigating complex reimbursement landscapes and regulatory environments has positioned her as a key architect of Adaptive's commercial success, including the successful FDA approval and broad payer coverage for clonoSEQ. Under Bobulsky's guidance, Adaptive's MRD business has seen exponential growth, with a tripling of test volumes in recent years and strategic collaborations that enhance real-world evidence generation. A graduate of the Wharton School with an MBA, she is a sought-after speaker on precision oncology and commercial innovation, committed to leveraging data-driven insights to transform cancer care.